AstraZeneca Will Get Humira Royalty Revenue Through CAT Deal

AstraZeneca's acquisition of Cambridge Antibody Technology will give the firm royalty revenues from human monoclonal antibody technologies already licensed out by CAT, including Abbott's rheumatoid arthritis therapy Humira (adalimumab)